This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Qian, J. Articles by Yi, Q. Search for Related Content PubMed PubMed Citation Articles by Qian, J. Articles by Yi, Q.

Targeting Heat Shock Proteins for Immunotherapy in Multiple Myeloma: Generation of Myeloma-Specific CTLs Using Dendritic Cells Pulsed with Tumor-Derived gp96

Authors' Affiliations: ¹ Myeloma Institute for Research and Therapy, Arkansas Cancer Research Center, University of Arkansas for Medical Sciences, Little Rock, Arkansas and ² Department of Hematopathology, University of Texas M.D. Anderson Cancer Center, Houston, Texas

Requests for reprints: Qing Yi, Department of Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 0903, Houston, TX 77030. Phone: 713-563-9065; Fax: 713-563-9241; E-mail: qyi{at}mdanderson.org.

Purpose: To develop effective immunotherapies for patients with multiple myeloma, it is important to use novel tumor antigens. Recent studies in solid tumors show that tumor-derived heat shock proteins (Hsp) can be used as immunogen; however, no such study has yet been reported in multiple myeloma.

Experimental Design: We examined whether myeloma-derived Hsp gp96 can be used as a myeloma antigen. Specific CTL lines were obtained after repeatedly stimulating T cells with autologous, HLA-A*0201⁺ dendritic cells pulsed with gp96 derived from HLA-A*0201⁺ human myeloma cell line (HMCL) U266 or primary myeloma cells.

Results: These T cells lysed not only gp96-pulsed dendritic cells, U266, and other HLA-A*0201⁺ HMCLs IM-9 and XG1 but also effectively killed HLA-A*0201⁺ primary myeloma cells from patients. No killing was observed against unpulsed dendritic cells, dendritic cells pulsed with control gp96, HLA-A*0201^– HMCLs, and primary myeloma cells, or HLA-A*0201⁺ nonmyeloma cells. Cytotoxicity was mainly MHC class I/HLA-A*0201 restricted, suggesting that the CTLs recognized gp96-chaperoned peptides on HLA-A*0201 that were derived from shared myeloma antigens and that myeloma cells naturally present these peptides in the context of their surface MHC molecules. Upon antigen stimulation, these T cells secreted IFN- and tumor necrosis factor-, indicating that they belong to type 1 T-cell subsets.

Conclusion: These results show that these T cells are potent CTLs that are able to effectively lyse myeloma cells but not normal blood cells and also suggest that Hsps from allogeneic tumor cells may be used as vaccines to immunize patients.

This article has been cited by other articles:

				H. Maeda, H. Sahara, Y. Mori, T. Torigo, K. Kamiguchi, Y. Tamura, Y. Tamura, K. Hirata, and N. Sato Biological Heterogeneity of the Peptide-binding Motif of the 70-kDa Heat Shock Protein by Surface Plasmon Resonance Analysis J. Biol. Chem., September 14, 2007; 282(37): 26956 - 26962. [Abstract] [Full Text] [PDF]

				J. Qian, J. Xie, S. Hong, J. Yang, L. Zhang, X. Han, M. Wang, F. Zhan, J. D. Shaughnessy Jr, J. Epstein, et al. Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma Blood, September 1, 2007; 110(5): 1587 - 1594. [Abstract] [Full Text] [PDF]

				S. Wang, S. Hong, J. Yang, J. Qian, X. Zhang, E. Shpall, L. W. Kwak, and Q. Yi Optimizing immunotherapy in multiple myeloma: restoring the function of patients' monocyte-derived dendritic cells by inhibiting p38 or activating MEK/ERK MAPK and neutralizing interleukin-6 in progenitor cells Blood, December 15, 2006; 108(13): 4071 - 4077. [Abstract] [Full Text] [PDF]